{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:22:52Z","timestamp":1791332572956,"version":"4.3.1"},"reference-count":192,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Idiopathic hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL) comprise a spectrum of indolent to aggressive diseases characterized by unexplained, persistent hypereosinophilia. These disorders have eluded a unique molecular explanation, and therapy has primarily been oriented toward palliation of symptoms related to organ involvement. Recent reports indicate that HES and CEL are imatinib-responsive malignancies, with rapid and complete hematologic remissions observed at lower doses than used in chronic myelogenous leukemia (CML). These BCR-ABL\u2013negative cases lack activating mutations or abnormal fusions involving other known target genes of imatinib, implicating a novel tyrosine kinase in their pathogenesis. A bedside-to-benchtop translational research effort led to the identification of a constitutively activated fusion tyrosine kinase on chromosome 4q12, derived from an interstitial deletion, that fuses the platelet-derived growth factor receptor-\u03b1 gene (PDGFRA) to an uncharacterized human gene FIP1-like-1 (FIP1L1). However, not all HES and CEL patients respond to imatinib, suggesting disease heterogeneity. Furthermore, approximately 40% of responding patients lack the FIP1L1-PDGFRA fusion, suggesting genetic heterogeneity. This review examines the current state of knowledge of HES and CEL and the implications of the FIP1L1-PDGFRA discovery on their diagnosis, classification, and management. (Blood. 2004;103:2879-2891)<\/jats:p>","DOI":"10.1182\/blood-2003-06-1824","type":"journal-article","created":{"date-parts":[[2003,11,25]],"date-time":"2003-11-25T01:14:27Z","timestamp":1069722867000},"page":"2879-2891","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":243,"title":["The FIP1L1-PDGFR\u03b1 fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management"],"prefix":"10.1182","volume":"103","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cools","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James M.","family":"Malone","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley L.","family":"Schrier","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gary","family":"Gilliland","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Coutre\u0301","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222162368100_REF1","doi-asserted-by":"crossref","unstructured":"Bain BJ. Hypereosinophilia. Curr Opin Hematol.2000;7: 21-25.","DOI":"10.1097\/00062752-200001000-00005"},{"key":"2020021222162368100_REF2","doi-asserted-by":"crossref","unstructured":"Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic hypereosinophilia. N Engl J Med.1999;341: 1112-1120.","DOI":"10.1056\/NEJM199910073411503"},{"key":"2020021222162368100_REF3","doi-asserted-by":"crossref","unstructured":"Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med.2003;348: 1201-1214.","DOI":"10.1056\/NEJMoa025217"},{"key":"2020021222162368100_REF4","doi-asserted-by":"crossref","unstructured":"Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med.1982;97: 78-92.","DOI":"10.7326\/0003-4819-97-1-78"},{"key":"2020021222162368100_REF5","doi-asserted-by":"crossref","unstructured":"Alfaham MA, Ferguson SD, Sihra B, Davies J. The idiopathic hypereosinophilic syndrome. Arch Dis Child.1987;62: 601-613.","DOI":"10.1136\/adc.62.6.601"},{"key":"2020021222162368100_REF6","doi-asserted-by":"crossref","unstructured":"Wynn SR, Sachs MI, Keating MU, et al. Idiopathic hypereosinophilic syndrome in a 5 1\/2-month-old infant. J Pediatr.1987;111: 94-97.","DOI":"10.1016\/S0022-3476(87)80352-9"},{"key":"2020021222162368100_REF7","doi-asserted-by":"crossref","unstructured":"Bakhshi S, Hamre M, Mohamed AM, Feldman G, Ravindranath Y. t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia. J Pediatr Hematol Oncol.2003;25: 82-84.","DOI":"10.1097\/00043426-200301000-00017"},{"key":"2020021222162368100_REF8","doi-asserted-by":"crossref","unstructured":"Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med.1968;68: 1220-1229.","DOI":"10.7326\/0003-4819-68-6-1220"},{"key":"2020021222162368100_REF9","doi-asserted-by":"crossref","unstructured":"Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine.1975;54: 1-27.","DOI":"10.1097\/00005792-197501000-00001"},{"key":"2020021222162368100_REF10","unstructured":"Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization of Tumours: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 29-31."},{"key":"2020021222162368100_REF11","doi-asserted-by":"crossref","unstructured":"Forrest DL, Horsman DE, Jensen CL, et al. Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization. Cancer Genet Cytogenet.1998;107: 65-68.","DOI":"10.1016\/S0165-4608(98)00055-7"},{"key":"2020021222162368100_REF12","doi-asserted-by":"crossref","unstructured":"Goldman JM, Najfeld V, Th'ng, KH. Agar culture and chromosome analysis of eosinophilic leukaemia. J Clin Pathol.1975;28: 956-961.","DOI":"10.1136\/jcp.28.12.956"},{"key":"2020021222162368100_REF13","doi-asserted-by":"crossref","unstructured":"Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood.1999;93: 1651-1657.","DOI":"10.1182\/blood.V93.5.1651"},{"key":"2020021222162368100_REF14","doi-asserted-by":"crossref","unstructured":"Luppi M, Marasca R, Morselli M, Barozzi P, Torelli G. Clonal nature of hypereosinophilic syndrome. Blood.1994;84: 349-350.","DOI":"10.1182\/blood.V84.1.349.349"},{"key":"2020021222162368100_REF15","doi-asserted-by":"crossref","unstructured":"Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol.2003;121: 203-223.","DOI":"10.1046\/j.1365-2141.2003.04195.x"},{"key":"2020021222162368100_REF16","unstructured":"Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol.1996;95: 2-9."},{"key":"2020021222162368100_REF17","doi-asserted-by":"crossref","unstructured":"Brito-Babapulle F. Clonal eosinophilic disorders and the hypereosinophilic syndrome. Blood Rev.1997;11: 129-145.","DOI":"10.1016\/S0268-960X(97)90008-4"},{"key":"2020021222162368100_REF18","doi-asserted-by":"crossref","unstructured":"Roufosse F, Cogan R, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med.2003;54: 169-184.","DOI":"10.1146\/annurev.med.54.101601.152431"},{"key":"2020021222162368100_REF19","unstructured":"Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med.1983;52: 1-22."},{"key":"2020021222162368100_REF20","unstructured":"Lefebvre C, Bletry O, Degoulet P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris).1989;140: 253-257."},{"key":"2020021222162368100_REF21","doi-asserted-by":"crossref","unstructured":"Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood.1994;83: 2759-2779.","DOI":"10.1182\/blood.V83.10.2759.2759"},{"key":"2020021222162368100_REF22","doi-asserted-by":"crossref","unstructured":"Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood.1981;58: 1012-1020.","DOI":"10.1182\/blood.V58.5.1012.1012"},{"key":"2020021222162368100_REF23","doi-asserted-by":"crossref","unstructured":"Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet.1987;1: 643-647.","DOI":"10.1016\/S0140-6736(87)90412-0"},{"key":"2020021222162368100_REF24","unstructured":"Venge P, Dahl R, Hallgren R, Olsson I. Cationic proteins of human eosinophils and their role in the inflammatory reaction. In: Mahmoud AAF, Austen KF, eds. The Eosinophil in Health and Disease. New York, NY: Grune and Stratton; 1980: 131-144."},{"key":"2020021222162368100_REF25","doi-asserted-by":"crossref","unstructured":"Tanino M, Kitamura K, Ohta G, Yamamoto Y, Sugioka G. Hypereosinophilic syndrome with extensive myocardial involvement and mitral valve thrombus instead of mural thrombi. Acta Pathol Jpn.1983;33: 1233-1242.","DOI":"10.1111\/j.1440-1827.1983.tb02168.x"},{"key":"2020021222162368100_REF26","doi-asserted-by":"crossref","unstructured":"Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacement for hypereosinophilic syndrome. Cardiol Young.2002;12: 67-70.","DOI":"10.1017\/S1047951102000136"},{"key":"2020021222162368100_REF27","doi-asserted-by":"crossref","unstructured":"Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol.2000;86: 110-113.","DOI":"10.1016\/S0002-9149(00)00841-9"},{"key":"2020021222162368100_REF28","doi-asserted-by":"crossref","unstructured":"DePace NL, Nestico PF, Morganroth J, et al. Dilated cardiomyopathy in the idiopathic hypereosinophilic syndrome. Am J Cardiol.1983;52: 1359-1360.","DOI":"10.1016\/0002-9149(83)90605-7"},{"key":"2020021222162368100_REF29","doi-asserted-by":"crossref","unstructured":"Baratta L, Afeltra A, Delfino M, De Castro S, Giorgino F, Rossi-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy\u2014case report and review of the literature. Angiology.2002;53: 465-470.","DOI":"10.1177\/000331970205300414"},{"key":"2020021222162368100_REF30","doi-asserted-by":"crossref","unstructured":"Virmani R, Chun PK, Dunn BE, Hartmen D, McAllister HA. Eosinophilic constrictive pericarditis. Am Heart J.1984;107: 803-807.","DOI":"10.1016\/0002-8703(84)90340-5"},{"key":"2020021222162368100_REF31","doi-asserted-by":"crossref","unstructured":"Lui CY, Makoui C. Severe constrictive pericarditis as an unsuspected cause of death in a patient with idiopathic hypereosinophilic syndrome and restrictive cardiomyopathy. Clin Cardiol.1988;11: 502-504.","DOI":"10.1002\/clc.4960110713"},{"key":"2020021222162368100_REF32","doi-asserted-by":"crossref","unstructured":"Corssmit EP, Trip MD, Durrer JD. Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology.1999;91: 272-276.","DOI":"10.1159\/000006923"},{"key":"2020021222162368100_REF33","doi-asserted-by":"crossref","unstructured":"Hayashi S, Isobe M, Okubo Y, Suzuki J, Yazaki Y, Sekiguchi M. Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens. Heart Vessels.1999;14: 104-108.","DOI":"10.1007\/BF02481750"},{"key":"2020021222162368100_REF34","doi-asserted-by":"crossref","unstructured":"Ejima J, Ohmura I, Kaji Y, Tsuda Y, Kanaya S, Fujino T. Diffuse endocardial thrombus in left ventricle associated with a case of hypereosinophilic syndrome. Jpn Heart J.1991;32: 267-272.","DOI":"10.1536\/ihj.32.267"},{"key":"2020021222162368100_REF35","doi-asserted-by":"crossref","unstructured":"Harley JB, McIntosh XL, Kirklin JJ, et al. Atrioventricular valve replacement in the idiopathic hypereosinophilic syndrome. Am J Med.1982;73: 77-81.","DOI":"10.1016\/0002-9343(82)90929-9"},{"key":"2020021222162368100_REF36","doi-asserted-by":"crossref","unstructured":"Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg.1988;46: 570-571.","DOI":"10.1016\/S0003-4975(10)64701-7"},{"key":"2020021222162368100_REF37","doi-asserted-by":"crossref","unstructured":"Cameron J, Radford DJ, Howell J, O'Brien MF. Hypereosinophilic heart disease. Med J Aust.1985;143: 408-410.","DOI":"10.5694\/j.1326-5377.1985.tb123104.x"},{"key":"2020021222162368100_REF38","doi-asserted-by":"crossref","unstructured":"Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol.2001;45: 524-527.","DOI":"10.1046\/j.1440-1673.2001.00972.x"},{"key":"2020021222162368100_REF39","doi-asserted-by":"crossref","unstructured":"Rauch AE, Amyot KM, Dunn HG, Ng B, Wilner G. Hypereosinophilic syndrome and myocardial infarction in a 15-year-old. Pediatr Pathol Lab Med.1997;17: 469-486.","DOI":"10.1080\/15513819709168588"},{"key":"2020021222162368100_REF40","doi-asserted-by":"crossref","unstructured":"Kazmierowski JA, Chusid MJ, Parrillo JE, Fauci AS, Wolff SM. Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol.1978;114: 531-535.","DOI":"10.1001\/archderm.1978.01640160009003"},{"key":"2020021222162368100_REF41","doi-asserted-by":"crossref","unstructured":"DeYampert NM, Beck LA. Eosinophilia and multiple erythematous indurated plaques. Idiopathic hypereosinophilic syndrome (IHS). Arch Dermatol.1997;133: 1581-1584.","DOI":"10.1001\/archderm.133.12.1581"},{"key":"2020021222162368100_REF42","doi-asserted-by":"crossref","unstructured":"Newton JA, Singh AK, Greaves MW, Spry CJ. Aquagenic pruritis associated with the idiopathic hypereosinophilic syndrome. Br J Dermatol.1990;122: 103-106.","DOI":"10.1111\/j.1365-2133.1990.tb08246.x"},{"key":"2020021222162368100_REF43","doi-asserted-by":"crossref","unstructured":"Lee ML, Fischer G, Gow E. Hypereosinophilic syndrome presenting with erythroderma. Australas J Dermatol.1988;29: 95-101.","DOI":"10.1111\/j.1440-0960.1988.tb00371.x"},{"key":"2020021222162368100_REF44","doi-asserted-by":"crossref","unstructured":"Leiferman KM, O'Duffy JD, Perry HO, Greipp PR, Giuliani ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA.1982;247: 1018-1020.","DOI":"10.1001\/jama.1982.03320320054032"},{"key":"2020021222162368100_REF45","doi-asserted-by":"crossref","unstructured":"Parker CJ. Hypereosinophilic syndrome with cutaneous blisters and bowel necrosis. Australas J Dermatol.1988;29: 103-106.","DOI":"10.1111\/j.1440-0960.1988.tb00373.x"},{"key":"2020021222162368100_REF46","doi-asserted-by":"crossref","unstructured":"Fitzpatrick JE, Johnson C, Simon P, Owenby J. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. Am J Dermatopathol.1987;9: 419-422.","DOI":"10.1097\/00000372-198710000-00008"},{"key":"2020021222162368100_REF47","doi-asserted-by":"crossref","unstructured":"Narayan S, Ezughah F, Standen GR, Pawade J, Kennedy CTC. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol.1993;148: 817-820.","DOI":"10.1046\/j.1365-2133.2003.05309.x"},{"key":"2020021222162368100_REF48","unstructured":"Sanchez JL, Padilla MA. Hypereosinophilic syndrome. Cutis.1982;29: 490-495."},{"key":"2020021222162368100_REF49","doi-asserted-by":"crossref","unstructured":"Bogenrieder T, Griese DP, Schiffner R, et al. Well's syndrome associated with idiopathic hypereosinophilic syndrome. Br J Dermatol.1997;137: 978-982.","DOI":"10.1111\/j.1365-2133.1997.tb01563.x"},{"key":"2020021222162368100_REF50","doi-asserted-by":"crossref","unstructured":"Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med.1985;102: 109-114.","DOI":"10.7326\/0003-4819-102-1-109"},{"key":"2020021222162368100_REF51","doi-asserted-by":"crossref","unstructured":"Wichman A, Buchthal F, Pezeshkpour GH, Fauci AS. Peripheral neuropathy in hypereosinophilic syndrome. Neurology.1985;35: 1140-1145.","DOI":"10.1212\/WNL.35.8.1140"},{"key":"2020021222162368100_REF52","doi-asserted-by":"crossref","unstructured":"Kwon SU, Kim JC, Kim JS. Sequential magnetic resonance imaging findings in hypereosinophilia-induced encephalopathy. J Neurol.2001;248: 279-284.","DOI":"10.1007\/s004150170201"},{"key":"2020021222162368100_REF53","doi-asserted-by":"crossref","unstructured":"Kaplan PW, Waterbury L, Kawas C, Bolla-Wilson K, Durack D. Reversible dementia with idiopathic hypereosinophilic syndrome. Neurology.1989;39: 1388-1391.","DOI":"10.1212\/WNL.39.10.1388"},{"key":"2020021222162368100_REF54","doi-asserted-by":"crossref","unstructured":"Prick JJ, Gabreels-Festen AA, Korten JJ, van der Wiel TW. Neurological manifestations of the hypereosinophilic syndrome (HES). Clin Neurol Neurosurg.1988;90: 269-273.","DOI":"10.1016\/0303-8467(88)90036-4"},{"key":"2020021222162368100_REF55","doi-asserted-by":"crossref","unstructured":"Weaver DF, Hefferman LP, Purdy RA, Ing VW. Eosinophil-induced neurotoxicity: axonal neuropathy, cerebral infarction and dementia. Neurology.1988;38: 144-146.","DOI":"10.1212\/WNL.38.1.144"},{"key":"2020021222162368100_REF56","doi-asserted-by":"crossref","unstructured":"Diaz F, Collazos J. Reversible cerebellar involvement in the idiopathic hypereosinophilic syndrome. Postgrad Med J.1999;75: 477-479.","DOI":"10.1136\/pgmj.75.886.477"},{"key":"2020021222162368100_REF57","doi-asserted-by":"crossref","unstructured":"Weingarten JS, O'Sheal SF, Margolis WS. Eosinophilic meningitis and the hypereosinophilic syndrome. Case report and review of the literature. Am J Med.1985;78: 674-676.","DOI":"10.1016\/0002-9343(85)90412-7"},{"key":"2020021222162368100_REF58","doi-asserted-by":"crossref","unstructured":"Slabbynck H, Impens N, Naegels S, Dewaele M, Schandevyl W. Idiopathic hypereosinophilic syndrome-related pulmonary involvement diagnosed by bronchoalveolar lavage. Chest.1992;101: 1178-1180.","DOI":"10.1378\/chest.101.4.1178"},{"key":"2020021222162368100_REF59","doi-asserted-by":"crossref","unstructured":"Cordier JF, Faure M, Hermier C, Brune J. Pleural effusions in an overlap syndrome of idiopathic hypereosinophilic syndrome and erythema elevatum diutinum. Eur Respir J.1990;3: 115-118.","DOI":"10.1183\/09031936.93.03010115"},{"key":"2020021222162368100_REF60","doi-asserted-by":"crossref","unstructured":"Epstein DM, Taortaina V, Gefter WB, Miller WT. The hypereosinophilic syndrome. Radiology.1981;140: 59-62.","DOI":"10.1148\/radiology.140.1.6454164"},{"key":"2020021222162368100_REF61","doi-asserted-by":"crossref","unstructured":"Kang EY, Shim JJ, Kim JS, Kim KI. Pulmonary involvement of idiopathic hypereosinophilic syndrome: CT findings in five patients. J Comput Assist Tomogr.1997;21: 612-615.","DOI":"10.1097\/00004728-199707000-00016"},{"key":"2020021222162368100_REF62","doi-asserted-by":"crossref","unstructured":"Winn RE, Kollef MH, Meyer JI. Pulmonary involvement in the hypereosinophilic syndrome. Chest.1994;105: 656-660.","DOI":"10.1378\/chest.105.3.656"},{"key":"2020021222162368100_REF63","doi-asserted-by":"crossref","unstructured":"Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood.1981;58: 1021-1026.","DOI":"10.1182\/blood.V58.5.1021.1021"},{"key":"2020021222162368100_REF64","doi-asserted-by":"crossref","unstructured":"Nam KJ, Jung WJ, Choi JC, et al. Hepatic involvement in hypereosinophilia: sonographic findings. J Ultrasound Med.1999;18: 475-479.","DOI":"10.7863\/jum.1999.18.7.475"},{"key":"2020021222162368100_REF65","doi-asserted-by":"crossref","unstructured":"Foong A, Scholes JV, Gleich GJ, Kephart GM, Holt PR. Eosinophil-induced chronic active hepatitis in the idiopathic hypereosinophilic syndrome. Hepatology.1991;13: 1090-1094.","DOI":"10.1002\/hep.1840130614"},{"key":"2020021222162368100_REF66","doi-asserted-by":"crossref","unstructured":"Ung KA, Remotti H, Olsson R. Eosinophilic hepatic necrosis in hypereosinophilic syndrome. J Clin Gastroenterol.2000;31: 323-327.","DOI":"10.1097\/00004836-200012000-00011"},{"key":"2020021222162368100_REF67","doi-asserted-by":"crossref","unstructured":"Elouaer-Blanc L, Zafrani ES, Farcet JP, Saint-Marc Girardin MF, Mathieu D, Dhumeaux D. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med.1985;145: 751-753.","DOI":"10.1001\/archinte.1985.00360040189042"},{"key":"2020021222162368100_REF68","unstructured":"Grauer L, Padilla VM III, Bouza L, Barkin JS. Eosinophilic sclerosing cholangitis associated with hypereosinophilic syndrome. Am J Gastroenterol.1993;88: 1764-1769."},{"key":"2020021222162368100_REF69","doi-asserted-by":"crossref","unstructured":"Tajima K, Katagiri T. Deposits of eosinophil granule proteins in eosinophilic cholecystitis and eosinophilic colitis associated with hypereosinophilic syndrome. Dig Dis Sci.1996;41: 282-288.","DOI":"10.1007\/BF02093816"},{"key":"2020021222162368100_REF70","unstructured":"Dillon JF, Finlayson ND. Idiopathic hypereosinophilic syndrome presenting as intrahepatic cholestatic jaundice. Am J Gastroenterol.1994;89: 1254-1255."},{"key":"2020021222162368100_REF71","unstructured":"Binaghi M, Perrenoud F, Dhermy P, Coscas G. Hypereosinophilic syndrome with ocular involvement. J Fr Ophtalmol.1985;8: 309-314."},{"key":"2020021222162368100_REF72","doi-asserted-by":"crossref","unstructured":"Chaine G, Davies J, Kohner EM, Hawarth S, Spry CJ. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology.1982;89: 1348-1356.","DOI":"10.1016\/S0161-6420(82)34625-4"},{"key":"2020021222162368100_REF73","doi-asserted-by":"crossref","unstructured":"Farcet, JP, Binaghi M, Kuentz M, et al. A hypereosinophilic syndrome with retinal arteritis and tuberculosis. Arch Intern Med.1982;142: 625-627.","DOI":"10.1001\/archinte.1982.00340160205034"},{"key":"2020021222162368100_REF74","doi-asserted-by":"crossref","unstructured":"Bozkir N, Stern GA. Ocular manifestations of the idiopathic hypereosinophilic syndrome. Am J Ophthalmol.1992;113: 456-458.","DOI":"10.1016\/S0002-9394(14)76175-6"},{"key":"2020021222162368100_REF75","unstructured":"Catalano L, Scala A, Rotoli B. Adie's syndrome (benign pupillotonia) and hypereosinophilic syndrome. Haematologica.1988;73: 549."},{"key":"2020021222162368100_REF76","doi-asserted-by":"crossref","unstructured":"Vandewiele IA, Maeyaert BM, Van Cutsem EJ, Geboes KR, Knockaert DC. Massive eosinophilic ascites: differential diagnosis between idiopathic hypereosinophilic syndrome and eosinophilic gastroenteritis. Acta Clin Belg.1991;46: 37-41.","DOI":"10.1080\/17843286.1991.11718139"},{"key":"2020021222162368100_REF77","unstructured":"Bellaiche G, Fontaine H, Choudat L, Lusina D, Ley G. Slama JL. Pancreatic involvement, ascites and diarrhea in idiopathic hypereosinophilic syndrome. Gastroenterol Clin Biol.1997;21: 519-522."},{"key":"2020021222162368100_REF78","doi-asserted-by":"crossref","unstructured":"Shah AM, Joglekar M. Eosinophilic colitis as a complication of the hypereosinophilic syndrome. Postgrad Med J.1987;63: 485-487.","DOI":"10.1136\/pgmj.63.740.485"},{"key":"2020021222162368100_REF79","unstructured":"Prattichizzo FA, Bernini L. An idiopathic hypereosinophilic syndrome mimicking seronegative rheumatoid arthritis: 20 year follow-up with clinical and laboratory findings. Clin Exp Rheumatol.1992;10: 79-81."},{"key":"2020021222162368100_REF80","doi-asserted-by":"crossref","unstructured":"Brogadir SP, Goldwein MI, Schumacher HR. A hypereosinophilic syndrome mimicking rheumatoid arthritis. Am J Med.1980;69: 799-802.","DOI":"10.1016\/0002-9343(80)90456-8"},{"key":"2020021222162368100_REF81","doi-asserted-by":"crossref","unstructured":"Anders HJ, Schattenkirchner M. Destructive joint lesions and bursitis in idiopathic hypereosinophilic syndrome. Rheumatology (Oxford).1999;38: 185-186.","DOI":"10.1093\/rheumatology\/38.2.185"},{"key":"2020021222162368100_REF82","doi-asserted-by":"crossref","unstructured":"Atanes A, Fernandez V, Nunez R, et al. Idiopathic eosinophilic synovitis. Case report and review of the literature. Scand J Rheumatol.1996;25: 183-185.","DOI":"10.3109\/03009749609080013"},{"key":"2020021222162368100_REF83","doi-asserted-by":"crossref","unstructured":"Layzer RB, Shearn MA, Satya-Murti S. Eosinophilic polymyositis. Ann Neurol.1977;1: 65-71.","DOI":"10.1002\/ana.410010106"},{"key":"2020021222162368100_REF84","doi-asserted-by":"crossref","unstructured":"Takekawa M, Imai K, Adachi M, et al. Hypereosinophilic syndrome accompanied with necrosis of finger tips. Intern Med.1992;31: 1262-1266.","DOI":"10.2169\/internalmedicine.31.1262"},{"key":"2020021222162368100_REF85","doi-asserted-by":"crossref","unstructured":"Peison B, Benisch B, Lim M, Chin JC. Idiopathic hypereosinophilic syndrome with polymyositis. South Med J.1988;81: 403-406.","DOI":"10.1097\/00007611-198803000-00029"},{"key":"2020021222162368100_REF86","doi-asserted-by":"crossref","unstructured":"Pickering MC, Walport MJ. Eosinophilic myopathic syndromes. Curr Opin Rheumatol.1998;10: 504-510.","DOI":"10.1097\/00002281-199811000-00002"},{"key":"2020021222162368100_REF87","doi-asserted-by":"crossref","unstructured":"Hirszel P, Cashell AW, Whelan TV, Dolan R, Yoshihashi A. Urinary Charcot-Leyden crystals in the hypereosinophilic syndrome with acute renal failure. Am J Kidney Dis.1988;12: 319-322.","DOI":"10.1016\/S0272-6386(88)80227-0"},{"key":"2020021222162368100_REF88","unstructured":"Nakahara C, Kamoda T, Kinusaga H, et al. Simultaneous onset of nephrotic syndrome and insulin-dependent diabetes mellitus in a case with hypereosinophilia syndrome. Clin Nephrol.2000;53: 312-314."},{"key":"2020021222162368100_REF89","doi-asserted-by":"crossref","unstructured":"Choi YJ, Lee JD, Yang KH, et al. Immunotactoid glomerulopathy associated with hypereosinophilic syndrome. Am J Nephrol.1998;18: 337-343.","DOI":"10.1159\/000013362"},{"key":"2020021222162368100_REF90","doi-asserted-by":"crossref","unstructured":"Richardson P, Dickinson G, Nash S, Hoffman L, Steingart R, Germain M. Crescentic glomerulonephritis and eosinophilic interstitial infiltrates in a patient with hypereosinophilic syndrome. Postgrad Med J.1995;71: 175-178.","DOI":"10.1136\/pgmj.71.833.175"},{"key":"2020021222162368100_REF91","doi-asserted-by":"crossref","unstructured":"Cogan E, Schandene L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med.1994;330: 535-538.","DOI":"10.1056\/NEJM199402243300804"},{"key":"2020021222162368100_REF92","doi-asserted-by":"crossref","unstructured":"Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med.1996;183: 1071-1082.","DOI":"10.1084\/jem.183.3.1071"},{"key":"2020021222162368100_REF93","doi-asserted-by":"crossref","unstructured":"Brugnoni D, Airo P, Rossi G, et al. CD4+ T-cell population able to secrete large amounts of interleukin-5. Blood.1996;87: 1416-1422.","DOI":"10.1182\/blood.V87.4.1416.bloodjournal8741416"},{"key":"2020021222162368100_REF94","doi-asserted-by":"crossref","unstructured":"Roufosse F, Schandene L, Sibille C, et al. T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia. Blood.1999;94: 994-1002.","DOI":"10.1182\/blood.V94.3.994.415k26_994_1002"},{"key":"2020021222162368100_REF95","doi-asserted-by":"crossref","unstructured":"Bank I, Amariglio N, Reshef A, et al. The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes. Leuk Lymphoma.2001;42: 123-133.","DOI":"10.3109\/10428190109097684"},{"key":"2020021222162368100_REF96","doi-asserted-by":"crossref","unstructured":"Brugnoni D, Airo P, Tosoni C, et al. CD3-CD4+ cells with a Th2-like pattern of cytokine production in the peripheral blood of a patient with cutaneous T cell lymphoma. Leukemia.1997;11: 1983-1985.","DOI":"10.1038\/sj.leu.2400839"},{"key":"2020021222162368100_REF97","doi-asserted-by":"crossref","unstructured":"Roufosse F, Schandene L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol.2000;109: 540-548.","DOI":"10.1046\/j.1365-2141.2000.02097.x"},{"key":"2020021222162368100_REF98","doi-asserted-by":"crossref","unstructured":"Kawasaki A, Mizushima Y, Matsui S, Hoshino K, Yano S, Kitagawa M. A case of T-cell lymphoma accompanying marked eosinophilia, chronic eosinophilic pneumonia and eosinophilic pleural effusion. A case report. Tumori.1991;77: 527-530.","DOI":"10.1177\/030089169107700616"},{"key":"2020021222162368100_REF99","doi-asserted-by":"crossref","unstructured":"Endo M, Usuki K, Kitazume K, Iwabe K, Okuyama Y, Urabe A. Hypereosinophilic syndrome in Hodgkin's disease with increased granulocyte-macrophage colony-stimulating factor. Ann Hematol.1995;71: 313-314.","DOI":"10.1007\/BF01697986"},{"key":"2020021222162368100_REF100","doi-asserted-by":"crossref","unstructured":"Catovksy D, Bernasconi C, Verdonck PJ, et al. The association of eosinophilia with lymphoblastic leukaemia or lymphoma: a study of seven patients. Br J Haematol.1980;45: 523-534.","DOI":"10.1111\/j.1365-2141.1980.tb07174.x"},{"key":"2020021222162368100_REF101","unstructured":"Takai K, Sanada M. Hypereosinophilic syndrome evolving to acute lymphoblastic leukemia. Int J Hematol.1991;54: 231-239."},{"key":"2020021222162368100_REF102","doi-asserted-by":"crossref","unstructured":"Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol.2003;122: 173-179.","DOI":"10.1046\/j.1365-2141.2003.04458.x"},{"key":"2020021222162368100_REF103","doi-asserted-by":"crossref","unstructured":"Weinfeld A, Westin J, Swolin B. Ph1-negative eosinophilic leukemia with trisomy 8. Scand J Haematol.1977;18: 413-420.","DOI":"10.1111\/j.1600-0609.1977.tb02095.x"},{"key":"2020021222162368100_REF104","unstructured":"Guitard AM, Horschowski N, Mozziconacci MJ, et al. Hypereosinophilic syndrome in childhood: trisomy 8 and transformation to mixed acute leukaemia. Nouv Rev Fr Hematol.1994;35: 555-559."},{"key":"2020021222162368100_REF105","doi-asserted-by":"crossref","unstructured":"Quiquandon I, Claisse JF, Capiod JC, Delobel J, Prin L. Alpha-interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission. Blood.1995;85: 2284-2285.","DOI":"10.1182\/blood.V85.8.2284.bloodjournal8582284"},{"key":"2020021222162368100_REF106","doi-asserted-by":"crossref","unstructured":"Ma SK, Kwong YL, Shek TW, et al. The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol.1999;30: 864-868.","DOI":"10.1016\/S0046-8177(99)90149-1"},{"key":"2020021222162368100_REF107","doi-asserted-by":"crossref","unstructured":"Myint H, Chacko J, Mould S, Ross F, Oscier DG. Karyotypic evolution in a granulocytic sarcoma developing in a myeloproliferative disorder with a novel (3;4) translocation. Br J Haematol.1995;90: 462-464.","DOI":"10.1111\/j.1365-2141.1995.tb05176.x"},{"key":"2020021222162368100_REF108","doi-asserted-by":"crossref","unstructured":"Duell T, Mittermuller J, Schmetzer HM, Kolb HJ, Wilmanns W. Chronic myeloid leukemia associated hypereosinophilic syndrome with a clonal t(4;7)(q11;q32). Cancer Genet Cytogenet.1997;94: 91-94.","DOI":"10.1016\/S0165-4608(96)00203-8"},{"key":"2020021222162368100_REF109","doi-asserted-by":"crossref","unstructured":"Schoffski P, Ganser A, Pascheberg U, Busche G, Gaede B, Hertenstein B. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol.2000;79: 95-98.","DOI":"10.1007\/s002770050018"},{"key":"2020021222162368100_REF110","doi-asserted-by":"crossref","unstructured":"Pardanani A, Reeder T, Li CY, Tefferi A. Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res.2003;27: 883-885.","DOI":"10.1016\/S0145-2126(03)00065-1"},{"key":"2020021222162368100_REF111","doi-asserted-by":"crossref","unstructured":"Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD. Association of inversion 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. N Engl J Med.1983;309: 630-636.","DOI":"10.1056\/NEJM198309153091103"},{"key":"2020021222162368100_REF112","doi-asserted-by":"crossref","unstructured":"Swirsky DM, Li YS, Matthews JG, Flemans RJ, Rees JKH, Hayhoe FGJ. 8;21 translocation in acute granulocytic leukemia: cytological, cytochemical, and clinical features. Br J Haematol.1984;56: 199-213.","DOI":"10.1111\/j.1365-2141.1984.tb03948.x"},{"key":"2020021222162368100_REF113","doi-asserted-by":"crossref","unstructured":"Song HS, Park SK. A case of monosomy-7 eosinophilic leukemia and neurofibromatosis, terminated with disseminated cryptococcosis. Korean J Intern Med.1987;2: 131-134.","DOI":"10.3904\/kjim.1987.2.1.131"},{"key":"2020021222162368100_REF114","doi-asserted-by":"crossref","unstructured":"Harrington DS, Peterson C, Ness M, Sanger W, Smith DM, Vaughan W. Acute myelogenous leukemia with eosinophilic differentiation and trisomy-1. Am J Clin Pathol.1988;90: 464-469.","DOI":"10.1093\/ajcp\/90.4.464"},{"key":"2020021222162368100_REF115","doi-asserted-by":"crossref","unstructured":"Broustet A, Bernard P, Dachary D, et al. Acute eosinophilic leukemia with a translocation (10p+;11q-). Cancer Genet Cytogenet.1986;1: 327-333.","DOI":"10.1016\/0165-4608(86)90213-X"},{"key":"2020021222162368100_REF116","doi-asserted-by":"crossref","unstructured":"Bhambhani K, Inoue S, Tyrkus M, Gohle N. Acute myelomonocytic leukemia type M4 with bone marrow eosinophilia and t(5;16)(q33;q22). Cancer Genet Cytogenet.1986;20: 187-188.","DOI":"10.1016\/0165-4608(86)90128-7"},{"key":"2020021222162368100_REF117","doi-asserted-by":"crossref","unstructured":"Mecucci C, Bosly A, Michaux JL, Broeckaert-Van Orshoven A, Van den Berghe H. Acute nonlymphoblastic leukemia with bone marrow eosinophilia and structural anomaly of chromosome 16. Cancer Genet Cytogenet.1985;17: 359-363.","DOI":"10.1016\/0165-4608(85)90120-7"},{"key":"2020021222162368100_REF118","doi-asserted-by":"crossref","unstructured":"Matsushima T, Murakami H, Kim K, et al. Steroid-responsive pulmonary disorders associated with myelodysplastic syndromes with der(1q;7p) chromosomal abnormality. Am J Hematol.1995;50: 110-115.","DOI":"10.1002\/ajh.2830500207"},{"key":"2020021222162368100_REF119","unstructured":"La Starza R, Trubia M, Testoni N, et al. Clonal eosinophils are a morphologic hallmark of ETV6\/ABL1 positive acute myeloid leukemia. Haematologica.2002;87: 789-794."},{"key":"2020021222162368100_REF120","doi-asserted-by":"crossref","unstructured":"Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell.1994;77: 307-316.","DOI":"10.1016\/0092-8674(94)90322-0"},{"key":"2020021222162368100_REF121","doi-asserted-by":"crossref","unstructured":"Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med.2002;347: 481-487.","DOI":"10.1056\/NEJMoa020150"},{"key":"2020021222162368100_REF122","doi-asserted-by":"crossref","unstructured":"Sato H, Danbara M, Tamura M, Morita M. Eosinophilic leukemia with a t(2;5)(p23;q35) translocation. Br J Haematol.1994;87: 404-406.","DOI":"10.1111\/j.1365-2141.1994.tb04931.x"},{"key":"2020021222162368100_REF123","doi-asserted-by":"crossref","unstructured":"Darbyshire PJ, Shortland D, Swansbury GJ, Sadler J, Lawler SD, Chessells JM. A myeloproliferative disease in two infants associated with eosinophilia and chromosome t(1;5) translocation. Br J Haematol.1987;66: 483-486.","DOI":"10.1111\/j.1365-2141.1987.tb01331.x"},{"key":"2020021222162368100_REF124","doi-asserted-by":"crossref","unstructured":"Jani K, Kempski HM, Reeves BR. A case of myelodysplasia with eosinophilia having a translocation t(5;12)(q31;q13) restricted to myeloid cells but not involving eosinophils. Br J Haematol.1994;87: 57-60.","DOI":"10.1111\/j.1365-2141.1994.tb04870.x"},{"key":"2020021222162368100_REF125","doi-asserted-by":"crossref","unstructured":"Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol.2003;120: 251-256.","DOI":"10.1046\/j.1365-2141.2003.04051.x"},{"key":"2020021222162368100_REF126","doi-asserted-by":"crossref","unstructured":"Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood.2003;102: 4187-4190.","DOI":"10.1182\/blood-2003-04-1150"},{"key":"2020021222162368100_REF127","doi-asserted-by":"crossref","unstructured":"Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphoblastic leukemia with eosinophilia. Blood.1990;76: 285-289.","DOI":"10.1182\/blood.V76.2.285.285"},{"key":"2020021222162368100_REF128","doi-asserted-by":"crossref","unstructured":"Popovici C, Zhang B, Gregoire MJ, et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood.1999;93: 1381-1389.","DOI":"10.1182\/blood.V93.4.1381"},{"key":"2020021222162368100_REF129","doi-asserted-by":"crossref","unstructured":"Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood.2000;95: 1788-1796.","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796"},{"key":"2020021222162368100_REF130","doi-asserted-by":"crossref","unstructured":"Popovici C, Adelaide J, Ollendorff V, et al. Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13). Proc Natl Acad Sci U S A.1998;95: 5712-5717.","DOI":"10.1073\/pnas.95.10.5712"},{"key":"2020021222162368100_REF131","doi-asserted-by":"crossref","unstructured":"Demiroglu A, Steer EJ, Heath C, et al. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood.2001;98: 3778-3783.","DOI":"10.1182\/blood.V98.13.3778"},{"key":"2020021222162368100_REF132","doi-asserted-by":"crossref","unstructured":"Guasch G, Popovici C, Mugneret F, et al. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood.2003;101: 286-288.","DOI":"10.1182\/blood-2002-02-0577"},{"key":"2020021222162368100_REF133","doi-asserted-by":"crossref","unstructured":"Parrillo JE, Fauci AS, Wolff SM. Therapy of the hypereosinophilic syndrome. Ann Intern Med.1978;89: 167-172.","DOI":"10.7326\/0003-4819-89-2-167"},{"key":"2020021222162368100_REF134","unstructured":"Chusid MJ, Dale DC. Eosinophilic leukemia. Remission with vincristine and hydroxyurea. Am J Med.1975;59: 297-300."},{"key":"2020021222162368100_REF135","doi-asserted-by":"crossref","unstructured":"Cofrancesco E, Cortellaro M, Pogliani E, Boschetti C, Salavatore M, Polli EE. Response to vincristine treatment in a case of idiopathic hypereosinophilic syndrome with multiple clinical manifestations. Acta Haematol.1984;72: 21-25.","DOI":"10.1159\/000206350"},{"key":"2020021222162368100_REF136","doi-asserted-by":"crossref","unstructured":"Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in two patients with hypereosinophilic syndrome. Am J Pediatr Hematol Oncol.1992;14: 348-351.","DOI":"10.1097\/00043426-199211000-00012"},{"key":"2020021222162368100_REF137","doi-asserted-by":"crossref","unstructured":"Lee JH, Lee JW, Jang CS, et al. Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome. Yonsei Med J.2002;43: 267-270.","DOI":"10.3349\/ymj.2002.43.2.267"},{"key":"2020021222162368100_REF138","doi-asserted-by":"crossref","unstructured":"Smit AJ, van Essen LH, de Vries EG. Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer.1991;67: 2826-2827.","DOI":"10.1002\/1097-0142(19910601)67:11<2826::AID-CNCR2820671119>3.0.CO;2-#"},{"key":"2020021222162368100_REF139","doi-asserted-by":"crossref","unstructured":"Bourrat E, Lebbe C, Calvo F. Etoposide for treating the hypereosinophilic syndrome. Ann Intern Med.1994;121: 899-900.","DOI":"10.7326\/0003-4819-121-11-199412010-00022"},{"key":"2020021222162368100_REF140","unstructured":"Luciano L, Catalano L, Sarrantonio C, Guerriero A, Califano C, Rotoli B. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5). Haematologica.1999;84: 651-653."},{"key":"2020021222162368100_REF141","doi-asserted-by":"crossref","unstructured":"Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-\u03b1 in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol.1998;58: 137-141.","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<137::AID-AJH9>3.0.CO;2-T"},{"key":"2020021222162368100_REF142","doi-asserted-by":"crossref","unstructured":"Malbrain ML, Van den Bergh H, Zachee P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality. Br J Haematol.1996;92: 176-183.","DOI":"10.1046\/j.1365-2141.1996.00298.x"},{"key":"2020021222162368100_REF143","doi-asserted-by":"crossref","unstructured":"Butterfield JH, Gleich GJ. Response of six patients with idiopathic hypereosinophilic syndrome to interferon alpha. J Allergy Clin Immunol.1994;94: 1318-1326.","DOI":"10.1016\/0091-6749(94)90348-4"},{"key":"2020021222162368100_REF144","doi-asserted-by":"crossref","unstructured":"Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol.1998;77: 161-164.","DOI":"10.1007\/s002770050434"},{"key":"2020021222162368100_REF145","doi-asserted-by":"crossref","unstructured":"Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol.2000;27: 110-115.","DOI":"10.1111\/j.1346-8138.2000.tb02131.x"},{"key":"2020021222162368100_REF146","doi-asserted-by":"crossref","unstructured":"Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY. Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E), and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol.1983;131: 1300-1305.","DOI":"10.4049\/jimmunol.131.3.1300"},{"key":"2020021222162368100_REF147","doi-asserted-by":"crossref","unstructured":"Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest.1996;97: 309-315.","DOI":"10.1172\/JCI118417"},{"key":"2020021222162368100_REF148","doi-asserted-by":"crossref","unstructured":"Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood.1996;87: 2354-2360.","DOI":"10.1182\/blood.V87.6.2354.bloodjournal8762354"},{"key":"2020021222162368100_REF149","doi-asserted-by":"crossref","unstructured":"Zabel P, Schlaak M. Cyclosporin for hypereosinophilic syndrome. Ann Hematol.1991;62: 230-231.","DOI":"10.1007\/BF01729838"},{"key":"2020021222162368100_REF150","doi-asserted-by":"crossref","unstructured":"Nadarajah S, Krafchik B, Roifman C, Horgan-Bell C. Treatment of hypereosinophilic syndrome in a child using cyclosporine: implication for a primary T-cell abnormality. Pediatrics.1997;99: 630-633.","DOI":"10.1542\/peds.99.4.630"},{"key":"2020021222162368100_REF151","doi-asserted-by":"crossref","unstructured":"Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. 2-chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia.1997;11: 1386-1390.","DOI":"10.1038\/sj.leu.2400717"},{"key":"2020021222162368100_REF152","doi-asserted-by":"crossref","unstructured":"Vazquez L, Caballero D, Canizo CD, et al. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis. Bone Marrow Transplant.2000;25: 217-218.","DOI":"10.1038\/sj.bmt.1702102"},{"key":"2020021222162368100_REF153","doi-asserted-by":"crossref","unstructured":"Chockalingam A, Jalil A, Shadduck RK, Lister J. Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant.1999;23: 1093-1094.","DOI":"10.1038\/sj.bmt.1701783"},{"key":"2020021222162368100_REF154","doi-asserted-by":"crossref","unstructured":"Basara N, Markova J, Schmetzer B, et al. Chronic eosinophilic leukemia: successful treatment with an unrelated bone marrow transplantation. Leuk Lymphoma.1998;32: 189-193.","DOI":"10.3109\/10428199809059261"},{"key":"2020021222162368100_REF155","unstructured":"Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation. Bone Marrow Transplant.1995;15: 647-648."},{"key":"2020021222162368100_REF156","doi-asserted-by":"crossref","unstructured":"Esteva-Lorenzo FJ, Meehan KR, Spitzer TR, Mazumder A. Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome. Am J Hematol.1996;51: 164-165.","DOI":"10.1002\/(SICI)1096-8652(199602)51:2<164::AID-AJH12>3.0.CO;2-I"},{"key":"2020021222162368100_REF157","doi-asserted-by":"crossref","unstructured":"Sadoun A, Lacotte L, Delwail V, et al. Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis. Bone Marrow Transplant.1997;19: 741-743.","DOI":"10.1038\/sj.bmt.1700729"},{"key":"2020021222162368100_REF158","doi-asserted-by":"crossref","unstructured":"Juvonen E, Volin L, Kopenen A, Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant.2002;29: 457-458.","DOI":"10.1038\/sj.bmt.1703379"},{"key":"2020021222162368100_REF159","doi-asserted-by":"crossref","unstructured":"Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol.2002;119: 131-134.","DOI":"10.1046\/j.1365-2141.2002.03771.x"},{"key":"2020021222162368100_REF160","doi-asserted-by":"crossref","unstructured":"Archimbaud E, Guyotat D, Guillaume C, Godard J, Fiere D. Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation. Am J Hematol.1988;27: 302-303.","DOI":"10.1002\/ajh.2830270414"},{"key":"2020021222162368100_REF161","doi-asserted-by":"crossref","unstructured":"Fukushima T, Kuriyama K, Ito H, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol.1995;90: 213-215.","DOI":"10.1111\/j.1365-2141.1995.tb03404.x"},{"key":"2020021222162368100_REF162","doi-asserted-by":"crossref","unstructured":"Weyman AE, Rankin R, King H. Loeffler's endocarditis presenting as mitral and trucuspid stenosis. Am J Cardiol.1977;40: 438-444.","DOI":"10.1016\/0002-9149(77)90168-0"},{"key":"2020021222162368100_REF163","doi-asserted-by":"crossref","unstructured":"Chandra M, Pettigrew RI, Eley JW, Oshinski JN, Guyton RA. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. Ann Thorac Surg.1996;62: 1856-1858.","DOI":"10.1016\/S0003-4975(96)00947-2"},{"key":"2020021222162368100_REF164","doi-asserted-by":"crossref","unstructured":"Blacklock HA, Cleland, JF, Tan P, Pillai VM. The hypereosinophilic syndrome and leukapheresis. Ann Intern Med.1979;91: 650-651.","DOI":"10.7326\/0003-4819-91-4-650_2"},{"key":"2020021222162368100_REF165","doi-asserted-by":"crossref","unstructured":"Davies J, Spry C. Plasma exchange or leukapheresis in the hypereosinophilic syndrome. Ann Intern Med.1982;96: 791.","DOI":"10.7326\/0003-4819-96-6-791_1"},{"key":"2020021222162368100_REF166","unstructured":"Chambers LA, Leonard SS, Whatmough AE, Weller PF, Bubley GJ, Kruskall MS. Management of hypereosinophilic syndrome with chronic plasma- and leukapheresis. Prog Clin Biol Res.1990;337: 83-85."},{"key":"2020021222162368100_REF167","doi-asserted-by":"crossref","unstructured":"Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res.2002;26: 881-884.","DOI":"10.1016\/S0145-2126(02)00046-2"},{"key":"2020021222162368100_REF168","doi-asserted-by":"crossref","unstructured":"Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med.1998;91: 492-493.","DOI":"10.1177\/014107689809100912"},{"key":"2020021222162368100_REF169","unstructured":"Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed.2001;3: 9."},{"key":"2020021222162368100_REF170","doi-asserted-by":"crossref","unstructured":"Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet.2002;359: 1577-1578.","DOI":"10.1016\/S0140-6736(02)08505-7"},{"key":"2020021222162368100_REF171","doi-asserted-by":"crossref","unstructured":"Pardanani A, Reeder T, Porrata L, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood.2003;101: 3391-3397.","DOI":"10.1182\/blood-2002-10-3103"},{"key":"2020021222162368100_REF172","doi-asserted-by":"crossref","unstructured":"Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood.2003;101: 4714-4716.","DOI":"10.1182\/blood-2003-01-0081"},{"key":"2020021222162368100_REF173","doi-asserted-by":"crossref","unstructured":"Preker PJ, Lingner J, Minvielle-Sebastia L, Keller W. The FIP1 gene encodes a component of a yeast pre-mRNA polyadenylation factor that directly interacts with poly(A) polymerase. Cell.1995;81: 379-389.","DOI":"10.1016\/0092-8674(95)90391-7"},{"key":"2020021222162368100_REF174","doi-asserted-by":"crossref","unstructured":"Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood.2003;101: 4660-4666.","DOI":"10.1182\/blood-2003-01-0006"},{"key":"2020021222162368100_REF175","doi-asserted-by":"crossref","unstructured":"Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood.2004;103: 473-478.","DOI":"10.1182\/blood-2003-08-2798"},{"key":"2020021222162368100_REF176","doi-asserted-by":"crossref","unstructured":"Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy. Blood.2003;102: 3093-3096.","DOI":"10.1182\/blood-2003-05-1627"},{"key":"2020021222162368100_REF177","doi-asserted-by":"crossref","unstructured":"Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A.2003;100: 7830-7835.","DOI":"10.1073\/pnas.0932698100"},{"key":"2020021222162368100_REF178","doi-asserted-by":"crossref","unstructured":"Helmling S, Zhelkovsky A, Moore CL. Fip1 regulates the activity of Poly(A) polymerase through multiple interactions. Mol Cell Biol.2001;21: 2026-2037.","DOI":"10.1128\/MCB.21.6.2026-2037.2001"},{"key":"2020021222162368100_REF179","doi-asserted-by":"crossref","unstructured":"Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRA-induced myeloproliferative disease. Cancer Cell.2003;3: 459-469.","DOI":"10.1016\/S1535-6108(03)00108-9"},{"key":"2020021222162368100_REF180","doi-asserted-by":"crossref","unstructured":"Valgeirsdottir S, Paukku K, Silvennoinen O, Heldin CH, Claesson-Welsh L. Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene.1998;16: 505-515.","DOI":"10.1038\/sj.onc.1201555"},{"key":"2020021222162368100_REF181","doi-asserted-by":"crossref","unstructured":"Yu J, Deuel TF, Kim HR. Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta -induced phenotypic transformation. J Biol Chem.2000;275: 19076-19082.","DOI":"10.1074\/jbc.M910329199"},{"key":"2020021222162368100_REF182","doi-asserted-by":"crossref","unstructured":"Yang J, Symes K, Mercola M, Schreiber SL. Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment. Curr Biol.1998;8: 11-18.","DOI":"10.1016\/S0960-9822(98)70015-6"},{"key":"2020021222162368100_REF183","doi-asserted-by":"crossref","unstructured":"McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol.1993;13: 7587-7595.","DOI":"10.1128\/MCB.13.12.7587"},{"key":"2020021222162368100_REF184","doi-asserted-by":"crossref","unstructured":"Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL\/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Natl Acad Sci U S A.1996;93: 14845-14850.","DOI":"10.1073\/pnas.93.25.14845"},{"key":"2020021222162368100_REF185","doi-asserted-by":"crossref","unstructured":"Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol.1996;16: 4107-4116.","DOI":"10.1128\/MCB.16.8.4107"},{"key":"2020021222162368100_REF186","doi-asserted-by":"crossref","unstructured":"Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood.2001;97: 3910-3918.","DOI":"10.1182\/blood.V97.12.3910"},{"key":"2020021222162368100_REF187","doi-asserted-by":"crossref","unstructured":"Ross TS, Gilliland DG. Transforming properties of the Huntingtin interacting protein 1\/platelet-derived growth factor beta receptor fusion protein. J Biol Chem.1999;274: 22328-22336.","DOI":"10.1074\/jbc.274.32.22328"},{"key":"2020021222162368100_REF188","doi-asserted-by":"crossref","unstructured":"Lacronique V, Boureaux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science.1997;278: 1309-1312.","DOI":"10.1126\/science.278.5341.1309"},{"key":"2020021222162368100_REF189","doi-asserted-by":"crossref","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood.2002;100: 1532-1542.","DOI":"10.1182\/blood-2002-02-0492"},{"key":"2020021222162368100_REF190","doi-asserted-by":"crossref","unstructured":"Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations in c-kit in human gastrointestinal tumors. Science.1998;279: 577-580.","DOI":"10.1126\/science.279.5350.577"},{"key":"2020021222162368100_REF191","doi-asserted-by":"crossref","unstructured":"Irusta PM, Luo Y, Bakht O, Lai CC, Smith SO, DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J Biol Chem.2002;277: 38627-38634.","DOI":"10.1074\/jbc.M204890200"},{"key":"2020021222162368100_REF192","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science.2003;299: 708-710.","DOI":"10.1126\/science.1079666"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/8\/2879\/1698838\/zh800804002879.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/8\/2879\/1698838\/zh800804002879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T14:34:08Z","timestamp":1682606048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/8\/2879\/18046\/The-FIP1L1PDGFR%CE%B1-fusion-tyrosine-kinase-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,15]]},"references-count":192,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-06-1824","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,15]]}}}